UK Edition
AdvertiseSubmit Company
Pharma JournalEvidence-Based Pharmaceutical Intelligence
CELL & GENE THERAPY

ABL

Biologics development and manufacturing contract services

ABL logo

ABL

Cell & Gene TherapyUnited States

Biologics development and manufacturing contract services

Visit WebsiteContact Company

About ABL

ABL specialises in the development and manufacture of advanced biological therapeutics, with a particular focus on gene therapies, vaccines, oncolytics and immunotherapies. Working exclusively with client programmes rather than proprietary pipelines, the company positions itself as a dedicated development partner for organisations tackling some of the most complex disease areas in modern medicine.

The company's manufacturing capabilities span virus manufacturing and process development, aseptic fill finish, and cell and virus banking. These services are supported by biologics and quality control testing, giving clients access to an integrated development pathway under a single provider. ABL also supplies ELISA kits as commercial products, reflecting a broader engagement with laboratory and analytical workflows.

Government partnering is listed as a distinct service category, indicating that ABL works with public-sector and defence-adjacent clients in addition to commercial biotechnology and pharmaceutical sponsors. This positions the company within the wider landscape of biodefence and public health preparedness, alongside conventional clinical-stage biologics work.

The organisation operates under the ABL, Inc. legal identity and maintains multiple locations, supporting projects across process development, manufacturing scale-up, and aseptic production. Its integrated service model is suited to sponsors requiring continuity across early development and late-stage manufacturing without transferring programmes between providers.

Further information is available at ablinc.com.

Areas of Expertise

Gene TherapyImmunotherapyVaccines

Services & Capabilities

Gene TherapyImmunotherapyVaccines
Similar Companies

More in Cell & Gene Therapy

A

Akron Biotech

Trusted by the cell and gene therapy sector since 2006, Akron Biotech supplies the ancillary materials that underpin advanced therapeutic manufacturing. Operating under the Akron Bio brand, the company occupies a specialised position in the biotech supply chain, providing the raw materials and contract services that research teams and commercial manufacturers depend on at every stage of development and scale-up. The product portfolio centres on three core categories: cytokines and growth factors, human plasma derived products, and media and media supplements. These materials are critical inputs for cell expansion, gene vector production, and the broader biomanufacturing workflows associated with advanced therapies. Alongside its catalogue offering, Akron Biotech runs dedicated manufacturing services covering proteins, media and buffers, and transfection and transduction reagents, giving clients a single source for both off-the-shelf supply and custom-manufactured components. Quality assurance is presented as a defining characteristic of the business. The company maintains regulatory support documentation and certificates for its materials, reflecting the compliance requirements of partners working in regulated therapeutic development environments. A knowledge centre comprising published posters, publications, and event resources further supports the scientific community using its products. Partnerships and collaborations form part of the company's stated commercial model, positioning Akron Biotech as an integrated supplier rather than a transactional vendor. Its leadership and newsroom functions suggest an active presence in the cell and gene therapy market rather than a passive catalogue role. Further information is available at akronbiotech.com.

View profile
4

4DMT

A proprietary vector discovery platform called Therapeutic Vector Evolution sits at the centre of 4DMT's approach to genetic medicine. Rather than relying on existing delivery vehicles, the clinical-stage biopharma company engineers customised, proprietary gene delivery vectors matched to specific tissue types and routes of administration, with the goal of addressing large-market diseases where conventional treatments fall short. Founded in 2015 and headquartered in Emeryville, California, 4DMT trades on NASDAQ under the ticker FDMT. 4DMT's integrated product engine spans design, development and manufacturing, enabling the company to build a diverse clinical pipeline. Current therapeutic focus spans retinal diseases and pulmonary diseases, two areas with significant unmet need in which precision gene delivery to targeted tissue is critical. The company positions its work as striving for potential curative outcomes rather than symptomatic management, reflecting its stated ambition to unlock the full potential of genetic medicine. As a clinical-stage organisation, 4DMT combines platform innovation with pipeline execution, maintaining a scientific advisory structure that includes a dedicated Retina Advisory Board alongside broader scientific and corporate advisory boards. The company also supports internal diversity through its 4Diversity programme, which shapes workforce culture and recruitment practices. Further information is available at 4dmoleculartherapeutics.com.

View profile
A

Albumedix

Rooted in decades of albumin science first pioneered at Delta Biotechnology and later advanced under Novozymes Biopharma, Albumedix is a Nottingham-based biotechnology company that produces recombinant human serum albumin for pharmaceutical and bioprocessing applications. The company emerged as an independent entity following Novozymes' divestment of its biopharma operations, carrying forward a well-established manufacturing and regulatory heritage. Its flagship material, Recombumin, is expressed in Saccharomyces cerevisiae yeast and is entirely free of animal-derived and plasma-derived components. This origin gives manufacturers a consistent, traceable alternative to plasma-sourced albumin, addressing both supply-chain risk and evolving regulatory expectations around animal-free raw materials in biopharmaceutical production. Applications Across Biologics Manufacturing Albumin-based excipients supplied by Albumedix are used as stabilisers in vaccines, cell and gene therapy products, and protein biologics, where formulation integrity directly affects product shelf life and clinical performance. Beyond final-product formulation, Recombumin is also incorporated into cell culture media and bioprocessing workflows, supporting the growth of sensitive mammalian cell lines used in biologics development. The company operates under pharmaceutical-grade quality systems, with its materials referenced in regulatory dossiers for licensed medicines across multiple markets. Albumedix works with global pharmaceutical manufacturers, contract development and manufacturing organisations, and advanced therapy developers seeking compliant, well-characterised albumin raw materials. Further information is available at albumedix.com.

View profile
AdvertisementTeksyte LTD

List Your Company

Showcase your company to thousands of pharma professionals.

Submit Listing

Advertise With Us

Reach decision-makers in the pharmaceutical industry.

Learn More

We use cookies and analytics to understand how the site is used and to keep the service free. Choose Accept All to allow this, or Essential Only to use just the cookies we need to keep the site working. You can change your choice any time in our Cookie Policy